DavidPhilipHudesmanMD

Gastroenterology • New York, NY

Inflammatory Bowel Disease

Associate Professor of Medicine, NYU School of Medicine Co-Director, Inflammatory Bowel Disease Center at NYU Langone Health

Join to view full profile

Dr. Hudesman is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Hudesman's full profile

Already have an account?

Office
305 East 33rd Street
New York, NY 10016

Education & Training

Icahn School of Medicine at Mount Sinai/Morningside/WestFellowship, Gastroenterology, 2008 - 2011
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2005 - 2008
Rutgers New Jersey Medical SchoolClass of 2005

Certifications & Licensure

NY State Medical License 2007 - 2026
CT State Medical License 2022 - 2024
FL State Medical License 2022 - 2024
PA State Medical License 2022 - 2024
American Board of Internal Medicine Gastroenterology

Clinical Trials

Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis Start of enrollment: 2012 Feb 01
Completed
Phase 2
Identify Predictors That Distinguish Between Tofacitinib Responders and Non-responders Based on Genotype and Cellular and Molecular Profiles From Pinch Biopsies, Blood and Stool Samples Start of enrollment: 2018 Dec 04
Completed

Publications & Presentations

PubMed

2 citations
Older Adults With Inflammatory Bowel Disease Are at Higher Risk of Developing Antibodies to Infliximab.
Adam S Faye, Kate E Lee, David Hudesman, Thierry Dervieux
Inflammatory Bowel Diseases. 2024-12-05
Tofacitinib Uptake by Patient-Derived Intestinal Organoids Predicts Individual Clinical Responsiveness.
Kyung Ku Jang, David Hudesman, Drew R Jones, P'ng Loke, Jordan E Axelrad
Gastroenterology. 2024-12-01
Ozanimod in Patients With Moderate to Severe Ulcerative Colitis Naive to Advanced Therapies.
Bruce E Sands, Geert D'Haens, Remo Panaccione, Miguel Regueiro, Subrata Ghosh
Clinical Gastroenterology and Hepatology. 2024-10-01

Journal Articles

Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
Leah Katta, Robert Hirten, Shannon Chang, Dana Lukin, Edward V Loftus, David Faleck, Arun Swaminath, William J Sandborn, Sashidhar Varma Sagi, Sunanda Kane, Prianka Ch..., Nature
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium
Gursimran Kochhar, Justin Hartke, Sashidhar Varma Sagi, Edward V Loftus, Joseph Meserve, Robert Hirten, David Faleck, Shannon Chang, Dana Lukin, Farhad Peerani, Leah K..., Nature

Press Mentions

IBD Drive Time: David Hudesman, MD, on Work Productivity in IBDSeptember 19th, 2024
Ulcerative Colitis: AI Program Shows Promise in Predicting Flare-UpsMarch 7th, 2023
What Is Inflammatory Bowel Disease?November 7th, 2018
Join now to see all

Committees

Cochair, CCFA Medical Advisory Committee - NYC Chapter

Professional Memberships